Cargando…
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ferrata Storti Foundation
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545833/ https://www.ncbi.nlm.nih.gov/pubmed/31126963 http://dx.doi.org/10.3324/haematol.2019.218883 |